The University of Southampton
University of Southampton Institutional Repository

Maintenance hormone therapy with Letrozole after first-line chemotherapy for advanced breast cancer.

Maintenance hormone therapy with Letrozole after first-line chemotherapy for advanced breast cancer.
Maintenance hormone therapy with Letrozole after first-line chemotherapy for advanced breast cancer.
Objectives: Maintenance hormone therapy after first-line chemotherapy is routinely used by many clinicians in advanced breast cancer patients with potentially hormone-sensitive tumors, although there are insufficient evidences in the literature to support this practice. We investigated the effects of the third-generation aromatase inhibitor letrozole as a maintenance therapy in postmenopausal patients who had responded or had stable disease with first-line chemotherapy. Methods: Fifty-eight patients (median age 62 years, range 31-80) were recruited and received letrozole, 2.5 mg/day starting within 8 weeks since the last cycle of chemotherapy. Estrogen and/or progesterone receptor status was positive in 81% of the patients, unknown in 19%; 57% of the patients had visceral disease. First-line chemotherapy included anthracyclines and/or taxanes in 74% of cases. Results: The median time to progression (TTP) from starting letrozole was 18.5 months. A shorter TTP was found in patients with abnormal CA 15-3 levels at the start of maintenance letrozole (median TTP, 9.9 months: p = 0.01), or with levels increasing >25% from baseline during the first 6 months of letrozole therapy (median TTP, 8.2 months: p < 0.0001). Response status improved during letrozole in 15.5% of patients who had obtained less than a complete response to chemotherapy. Maintenance treatment was well tolerated and had no significant impact on quality of life scores. Conclusions: This study provides evidence in support of the common clinical practice of maintenance hormone therapy after chemotherapy in suitably selected patients with advanced breast cancer.
advanced breast cancer, CA 15-3, Letrozole, maintenance therapy
0030-2414
364-370
Bertelli, Gianfilippo
0c0e4174-4f9a-49e9-94d1-bc18f1fdeecf
Garrone, Ornella
9a31cf8b-ae39-4f6d-ba8e-4c7a16ab00a6
Bertolotti, Laura
4ae03dc5-0f0e-4453-ac03-83d487ba79c4
Occelli, Marcella
8a4b77a4-c7ae-4bb9-9f1b-4117fb828aa7
Conforti, Serafino
bbe79117-fdbc-4128-b5d5-7c34617d9c32
Marzano, Nicola
a389237b-fa65-4c03-aaaf-3196d67bf0fb
Febbraro, Antonio
7087731e-7996-4c49-a2a2-cbd794e20be5
Carlini, Paolo
bed97c0e-3942-4dd3-8db4-8bedb83379fe
Liossi, Christina
fd401ad6-581a-4a31-a60b-f8671ffd3558
del Mastro, Lucia
e77e7042-660c-4908-94bd-e9707d2ea399
Leonard, Robert C.F.
7139b5ea-a1cf-4c41-b53e-01ab258bc4e5
Bertelli, Gianfilippo
0c0e4174-4f9a-49e9-94d1-bc18f1fdeecf
Garrone, Ornella
9a31cf8b-ae39-4f6d-ba8e-4c7a16ab00a6
Bertolotti, Laura
4ae03dc5-0f0e-4453-ac03-83d487ba79c4
Occelli, Marcella
8a4b77a4-c7ae-4bb9-9f1b-4117fb828aa7
Conforti, Serafino
bbe79117-fdbc-4128-b5d5-7c34617d9c32
Marzano, Nicola
a389237b-fa65-4c03-aaaf-3196d67bf0fb
Febbraro, Antonio
7087731e-7996-4c49-a2a2-cbd794e20be5
Carlini, Paolo
bed97c0e-3942-4dd3-8db4-8bedb83379fe
Liossi, Christina
fd401ad6-581a-4a31-a60b-f8671ffd3558
del Mastro, Lucia
e77e7042-660c-4908-94bd-e9707d2ea399
Leonard, Robert C.F.
7139b5ea-a1cf-4c41-b53e-01ab258bc4e5

Bertelli, Gianfilippo, Garrone, Ornella, Bertolotti, Laura, Occelli, Marcella, Conforti, Serafino, Marzano, Nicola, Febbraro, Antonio, Carlini, Paolo, Liossi, Christina, del Mastro, Lucia and Leonard, Robert C.F. (2005) Maintenance hormone therapy with Letrozole after first-line chemotherapy for advanced breast cancer. Oncology, 68 (4-6), 364-370. (doi:10.1159/000086976).

Record type: Article

Abstract

Objectives: Maintenance hormone therapy after first-line chemotherapy is routinely used by many clinicians in advanced breast cancer patients with potentially hormone-sensitive tumors, although there are insufficient evidences in the literature to support this practice. We investigated the effects of the third-generation aromatase inhibitor letrozole as a maintenance therapy in postmenopausal patients who had responded or had stable disease with first-line chemotherapy. Methods: Fifty-eight patients (median age 62 years, range 31-80) were recruited and received letrozole, 2.5 mg/day starting within 8 weeks since the last cycle of chemotherapy. Estrogen and/or progesterone receptor status was positive in 81% of the patients, unknown in 19%; 57% of the patients had visceral disease. First-line chemotherapy included anthracyclines and/or taxanes in 74% of cases. Results: The median time to progression (TTP) from starting letrozole was 18.5 months. A shorter TTP was found in patients with abnormal CA 15-3 levels at the start of maintenance letrozole (median TTP, 9.9 months: p = 0.01), or with levels increasing >25% from baseline during the first 6 months of letrozole therapy (median TTP, 8.2 months: p < 0.0001). Response status improved during letrozole in 15.5% of patients who had obtained less than a complete response to chemotherapy. Maintenance treatment was well tolerated and had no significant impact on quality of life scores. Conclusions: This study provides evidence in support of the common clinical practice of maintenance hormone therapy after chemotherapy in suitably selected patients with advanced breast cancer.

Text
40269.pdf - Version of Record
Restricted to Repository staff only
Request a copy

More information

Published date: 2005
Keywords: advanced breast cancer, CA 15-3, Letrozole, maintenance therapy

Identifiers

Local EPrints ID: 40269
URI: http://eprints.soton.ac.uk/id/eprint/40269
ISSN: 0030-2414
PURE UUID: 9a78afbb-3eca-4100-82b2-9dbd7c4235b5
ORCID for Christina Liossi: ORCID iD orcid.org/0000-0003-0627-6377

Catalogue record

Date deposited: 04 Jul 2006
Last modified: 24 Sep 2019 00:45

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×